CHILDRENS CANCER GROUP

在这个拨款周期中，费城儿童医院（CHOP）将继续其过去30年对CCG的捐款。具体而言，CHOP将为大量患者进行治疗试验，努力为生物和转化研究提供患者样本，开展机构和ccg相关的试点研究，并提供大量不同类型的年轻和成熟人才和科学领导。在过去的周期中，CHOP的神经肿瘤学先导研究是4个CCG I期和II期研究的模板。在这个周期中，神经肿瘤学项目将介绍新的递送途径，靶向治疗和探索1型神经纤维瘤病（NF-1），以探索遗传学和脑肿瘤的界面。与神经肿瘤学项目合作，神经母细胞瘤项目将开发TRK受体组用于诊断、预后和治疗。在CHOP前期研究的基础上，白血病组将向CCG提出对中枢神经系统复发和已建立的中枢神经系统疾病进行长时间、低剂量颅脊髓照射，并将引入重复再诱导/再巩固策略治疗骨髓复发。CCG支持的CHOP白血病实验室研究包括治疗相关性白血病和婴儿白血病的遗传流行病学以及小儿骨髓增生异常和骨髓增生性综合征。CHOP实体肿瘤组的间隔压缩试点研究正在纳入下一个III期Ewing试验。t（2;13）和其他融合基因的PCR分析将用于微小残留疾病的检测和靶向治疗的开发。肿瘤部门的新实验治疗项目将研究独特的生物制剂，如HLA独立的TALL-104细胞系、TRK靶向的CEP-751、IGFR可溶性受体和反义的IGF1受体。《排骨过渡方案》旨在成为幸存者后续行动的典范，促进良好的预防保健战略和良好的研究。第一项转移研究旨在确定继发恶性肿瘤患者的易感遗传风险因素。CHOP和CCG的相互作用是双向的，对两者都是有益的。

In this grant cycle, The Children's Hospital of Philadelphia (CHOP) will continue its previous 30 years of contributions to CCG. Specifically, CHOP will enter large numbers of patients on therapeutic trials, diligently supply patient samples for biologic and translational studies, carry out both institutional and CCG-linked pilot studies, and provide a vast and varied repetoire of young and mature talent and scientific leadership. In the past cycle, CHOP's Neuro-Oncology pilot studies were templates for 4 CCG Phase I and Phase II studies. In this cycle the Neuro-Oncology Program will introduce novel routes of delivery, targetted therapy, and exploration of neurofibromatosis type 1(NF-1) to probe the interface of genetics and brain tumors. In collaboration with the Neuro-Oncology Program, the Neuroblastoma Program will develop the TRK group of receptors for diagnosis prognosis and therapy. Based on CHOP pilot studies, the Leukemia Group will propose to CCG protracted, reduced-dose craniospinal irradiation of CNS relapse and established CNS disease and will introduce the repetitive reinduction/reconsolidation strategy for marrow relapse. CCG- supported CHOP laboratory investigation in leukemia includes genetic epidemiology of treatment-related leukemias and infant leukemia and the pediatric myelodysplastic and myeloproliferative syndromes. The CHOP Solid Tumor Group's pilot study of interval compression is being incorporated into the next phase III Ewing's trial. PCR analysis of t(2;13) and other fusion genes will be used for detection of minimal residual disease and for development of targetted therapy. The Division of Oncology's new Experimental Therapeutics Program will investigate unique biologics such as the HLA independent TALL-104 cell line, TRK targetted CEP-751, and IGFR soluble receptor and antisense the IGF1 receptor. CHOPs Transition Program aims to be a prototype for follow-up of survivors, promoting good preventive health strategies and good research. The first transition study seeks to define predisposing genetic risk factors in patients who have second malignant neoplasms. The interactions of CHOP and CCG are bidirectional and are mutually rewarding for both.